Onchilles Pharma’s (potentially) Groundbreaking Pan-Cancer Therapeutics: Targeting the ELANE Pathway

Early PSA Response as a Predictor and Mediator of Treatment Efficacy in Metastatic Hormone Sensitive Prostate Cancer

Phase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer

A Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer